Welcome to the Annual General Meeting of Spermosens AB, reg. no. 559179-0380, on June 16, 2025, at 10:00 PM at Scheeletorget 1, Medicon Village, The Spark, Lund. Registration for the meeting begins at 09:30 PM.
Read moreVälkommen till Spermosens AB:s, org. nr. 559179–0380, årsstämma den 16 juni 2025, kl. 10.00 på Scheeletorget 1, Medicon Village, The Spark, Lund. Inregistrering till stämman börjar kl. 09.30.
Read moreWe have made solid progress during the first quarter, marked by positive interim results from our ongoing clinical study and the successful completion of financing to support our activities.
Read moreSpermosens AB (“Spermosens” or the “Company”) provides an update on its ongoing clinical study, commercial discussions and financing.
Read moreSpermosens AB (“Spermosens” or the “Company”) announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company´s patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first interim analysis released in December 2024. Specifically, the results continue to demonstrate correlation between the JUNO binding and fertility outcomes.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team’s technology expertise is a key step in executing the Company’s recently announced plan to achieve positive cash flow from the second half of 2026.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) announces a strategic collaboration with Scalania AG (“Scalania”), part of the UNITY Innovation Alliance, to accelerate the development and market readiness of its unique JUNO-Checked technology. Following the previous announcement on March 4th, 2025, the Company has now entered into a strategic collaboration agreement with Scalania, effective from April 2025.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that a peer-reviewed article, “JUNO-Checked – A Live Cell Electrochemical Biosensor for Sperm Function Diagnostics,” has been published in the prestigious journal Sensors & Diagnostics by the Royal Society of Chemistry. This gold open-access journal is renowned for showcasing cutting-edge research on sensing technologies and diagnostic systems, with a particular focus on novel materials, innovative detection methods and advancements that enable in situ or real-world testing.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens aims to establish licensing agreements with leading players in the assisted reproductive technology (ART) market in the second half of 2026, positioning the company to achieve positive cash flow.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024.
Read moreSpermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income from license agreements with established partners in the global Assisted Reproductive Technology (ART) market.
Read moreSpermosens AB (“Spermosens” or “the Company”) announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025.
Read more
